The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic

被引:89
作者
Won, Jung-Hyun [1 ,2 ]
Lee, Howard [1 ,2 ,3 ,4 ,5 ]
机构
[1] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 03080, South Korea
[2] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Ctr Convergence Approaches Drug Dev, Seoul 03080, South Korea
[3] Seoul Natl Univ, Dept Clin Pharmacol & Therapeut, Coll Med, Seoul 03080, South Korea
[4] Seoul Natl Univ Hosp, Dept Clin Pharmacol & Therapeut, Seoul 03080, South Korea
[5] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Transdisciplinary Studies, Seoul 16229, South Korea
基金
新加坡国家研究基金会;
关键词
SARS-CoV-2; COVID-19; drug repositioning; vaccine; public health crisis; RESPIRATORY SYNDROME; CORONAVIRUS; CHLOROQUINE; VIRUS; LOPINAVIR/RITONAVIR; EPIDEMIOLOGY; TECHNOLOGIES; EFFICACY; TRIAL; SARS;
D O I
10.3390/ijms21249775
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world has vehemently worked to develop treatments and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented speed. Few of the repositioned drugs for COVID-19 have shown that they were efficacious and safe. In contrast, a couple of vaccines against SARS-CoV-2 will be ready for mass rollout early next year. Despite successful vaccine development for COVID-19, the world will face a whole new set of challenges including scale-up manufacturing, cold-chain logistics, long-term safety, and low vaccine acceptance. We highlighted the importance of knowledge sharing and collaboration to find innovative answers to these challenges and to prepare for newly emerging viruses.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 132 条
[1]   Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) [J].
Ahn, Dae-Gyun ;
Shin, Hye-Jin ;
Kim, Mi-Hwa ;
Lee, Sunhee ;
Kim, Hae-Soo ;
Myoung, Jinjong ;
Kim, Bum-Tae ;
Kim, Seong-Jun .
JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2020, 30 (03) :313-324
[2]   Current Status of COVID-19 Therapies and Drug Repositioning Applications [J].
Altay, Ozlem ;
Mohammadi, Elyas ;
Lam, Simon ;
Turkez, Hasan ;
Boren, Jan ;
Nielsen, Jens ;
Uhlen, Mathias ;
Mardinoglu, Adil .
ISCIENCE, 2020, 23 (07)
[3]  
[Anonymous], CLIN TRIAL EFF SAF I
[4]   Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania [J].
Anywaine, Zacchaeus ;
Whitworth, Hilary ;
Kaleebu, Pontiano ;
Praygod, George ;
Shukarev, Georgi ;
Manno, Daniela ;
Kapiga, Saidi ;
Grosskurth, Heiner ;
Kalluvya, Samuel ;
Bockstal, Viki ;
Anumendem, Dickson ;
Luhn, Kerstin ;
Robinson, Cynthia ;
Douoguih, Macaya ;
Watson-Jones, Deborah .
JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (01) :46-56
[5]   Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial [J].
Arabi, Yaseen M. ;
Alothman, Adel ;
Balkhy, Hanan H. ;
Al-Dawood, Abdulaziz ;
AlJohani, Sameera ;
Al Harbi, Shmeylan ;
Kojan, Suleiman ;
Al Jeraisy, Majed ;
Deeb, Ahmad M. ;
Assiri, Abdullah M. ;
Al-Hameed, Fahad ;
AlSaedi, Asim ;
Mandourah, Yasser ;
Almekhlafi, Ghaleb A. ;
Sherbeeni, Nisreen Murad ;
Elzein, Fatehi Elnour ;
Memon, Javed ;
Taha, Yusri ;
Almotairi, Abdullah ;
Maghrabi, Khalid A. ;
Qushmaq, Ismael ;
Al Bshabshe, Ali ;
Kharaba, Ayman ;
Shalhoub, Sarah ;
Jose, Jesna ;
Fowler, Robert A. ;
Hayden, Frederick G. ;
Hussein, Mohamed A. .
TRIALS, 2018, 19
[6]  
Arseniy Palagin Russian Direct Investment Fund, INV FUND 2 INT AN CL
[7]  
Arseniy Palagin Russian Direct Investment Fund, ASTRAZENECA WILL TES
[8]  
AstraZeneca, STAT ASTRAZENECA OXF
[9]  
AstraZeneca, ASTRAZENECA ADV RESP
[10]  
AstraZeneca, DEV VERS IMM PROGR C